<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468247</url>
  </required_header>
  <id_info>
    <org_study_id>AP2006-01</org_study_id>
    <nct_id>NCT00468247</nct_id>
  </id_info>
  <brief_title>Registration Enabling Study of the Safety and Efficacy of the Use of the Navigator Circulatory Management System</brief_title>
  <acronym>NAV-1</acronym>
  <official_title>A Prospective,Open,Multicentre,RCT to Assess the Safety &amp; Efficacy of Navigator v Conventional Care in Post-op Cardiac Surgery Patients Undergoing CABG &amp;/or Heart Valve Repair/Replacement Utilising Heart Lung Perfusion Pump(The NAV-1 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Physiology Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trident Clinical Research Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Applied Physiology Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, open, RCT to assess the safety and efficacy of the Navigator Guided&#xD;
      Circulatory Management System versus conventional care in post-operative cardiac surgery&#xD;
      patients. The purpose of the study is to demonstrate that the real time acquisition and&#xD;
      subsequent processing and display of data produced by the Navigator guided circulatory&#xD;
      management system provides the clinician with appropriate data and guidance to achieve and&#xD;
      maintain a prescribed target haemodynamic stability in the post operative patient when&#xD;
      compared to conventional care in an Intensive Care Unit setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol No. AP2006-01&#xD;
&#xD;
      Study title: A Prospective, Open, Randomised, Multicentre, Controlled Group Study to Assess&#xD;
      the Safety and Efficacy of Navigator versus Conventional Care in Postoperative Cardiac&#xD;
      Surgery Patients Undergoing Coronary Bypass Grafting and or Heart Valve Repair or Replacement&#xD;
      Utilizing Heart Lung Perfusion Pump.&#xD;
&#xD;
      Acronym: NAV 1&#xD;
&#xD;
      Type of study: Device Trial&#xD;
&#xD;
      Sponsor: Applied Physiology Pty Ltd&#xD;
&#xD;
      Study device: Navigator Guided Circulatory Care Management System&#xD;
&#xD;
      Route of Administration: Via Touch Panel Computer, externally connected to the bedside&#xD;
      physiological monitor in a critical care environment&#xD;
&#xD;
      Study centres: Six Australian centres&#xD;
&#xD;
      Study design: Multicentre, open, randomised, controlled group study&#xD;
&#xD;
      Total sample size: One hundred completed patients, 50 in each arm&#xD;
&#xD;
      Study population: Post operative coronary bypass and heart valve repair or replacement&#xD;
      patients admitted to a Cardiac Intensive Care or Intensive Care Unit. Surgery must involve&#xD;
      the use of a heart lung perfusion pump and the patient must have a functioning arterial line&#xD;
      and Swan Ganz catheter in situ to enable the measurement of Cardiac Output, Mean Arterial&#xD;
      Pressure, and Right Atrial Pressure.&#xD;
&#xD;
      Study regimen: Following surgery, and after meeting inclusion and exclusion criteria,&#xD;
      patients will be randomised on admission to ICU to receive care guided by Navigator or&#xD;
      conventional care during their ICU stay while CO is being monitored. All patients will be&#xD;
      connected to the Navigator; the screen of the patients in the control group will have the&#xD;
      graphical section blank, the right hand side will display actual values of MAP, CO and RAP as&#xD;
      slaved from the bedside monitor, along with the patient's screening and randomisation number&#xD;
      and initials. The arm of the study to which the patient has been randomised&#xD;
      ;control/Navigator, will also be shown.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary: The primary efficacy endpoint is the average distance to the central point of the&#xD;
      target cardiovascular zone over the period the patient is connected to Navigator.&#xD;
&#xD;
      Secondary: Secondary endpoints for the trial will be:&#xD;
&#xD;
        -  Percentage time in the target cardiovascular zone over the period the patient is&#xD;
           connected to the Navigator&#xD;
&#xD;
        -  Clinically significant atrial fibrillation over the period the patient is connected to&#xD;
           the Navigator. This is defined as irregular supraventricular rhythm with an absence of&#xD;
           discrete P waves lasting more than ten minutes documented and confirmed with an ECG&#xD;
&#xD;
        -  Multiple organ function, as assessed using the SOFA score, calculated daily&#xD;
&#xD;
        -  Navigator device related adverse events and device failures&#xD;
&#xD;
      Statistical analysis: The primary and secondary endpoints and all safety data will be&#xD;
      analysed on the randomised Intention-to-treat population.The ITT population will include all&#xD;
      individuals who are randomised. The analysis will compare the primary efficacy endpoint&#xD;
      between the two randomised treatment groups using independent t tests. The secondary analyses&#xD;
      will compare the secondary endpoints between the two randomised treatment groups using&#xD;
      independent t-tests, Chi-square tests and Fisher's exact tests as appropriate.&#xD;
&#xD;
      Study Period: From the first pre-surgery screening visit to the post operative follow up&#xD;
      visit, approximately six weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average distance to central point of the target cardiovascular zone while connected to the device</measure>
    <time_frame>Time connected to Navigator device</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage time in the target cardiovascular zone while connected to device</measure>
    <time_frame>Time connected to Navigator device</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant AF while connected to device</measure>
    <time_frame>Time connected to Navigator device</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple organ function (SOFA score)</measure>
    <time_frame>From connection to Navigator device to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related adverse events and device failures</measure>
    <time_frame>Time connected to Navigator device</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Critical Illness</condition>
  <condition>Intensive Care</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device , Navigator used for guiding haemodynamic care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Navigator</intervention_name>
    <description>Navigator circulatory mgt system</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional care</intervention_name>
    <description>Conventional haemodynamic care</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18 years or older&#xD;
&#xD;
          2. Undergoing elective cardiac surgery where surgery involves the use of a heart-lung&#xD;
             perfusion pump&#xD;
&#xD;
          3. Will have an arterial line and Swan Ganz catheter in situ&#xD;
&#xD;
          4. Require invasive measurement of Cardiac Output (CO), Mean Arterial Pressure (MAP) and&#xD;
             Right Atrial Pressure (RAP)&#xD;
&#xD;
          5. Are able and willing to provide written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are lactating or pregnant&#xD;
&#xD;
          2. Require Extracorporeal Membrane Oxygenation&#xD;
&#xD;
          3. Present at baseline screening or immediately prior to randomisation in the ICU with&#xD;
             atrial fibrillation (irregular supraventricular rhythm, not due to ectopic complexes&#xD;
             with an absence of discrete P-waves lasting more than 10 minutes documented and&#xD;
             confirmed with an ECG)&#xD;
&#xD;
          4. Intra-operative surgical treatment for atrial fibrillation&#xD;
&#xD;
          5. Surgery for left atrial reduction&#xD;
&#xD;
          6. Patients with left ventricular assist devices&#xD;
&#xD;
          7. Patients with permanent pacemakers in situ&#xD;
&#xD;
          8. Deemed by the investigator to be uncooperative or unsuitable for inclusion into this&#xD;
             trial&#xD;
&#xD;
          9. Have a medical condition that in the opinion of the investigator would jeopardise the&#xD;
             patient's safety by participating in this trial&#xD;
&#xD;
         10. Current participation in another drug or device study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yugan Mudaliar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Sydney Area Health Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geoff Parkin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Monash Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Public Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Private Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Public Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Public Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.applied-physiology.com</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Parkin WG. Volume state control - a new approach. Crit Care Resusc. 1999 Sep;1(3):311-21.</citation>
    <PMID>16603021</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 30, 2007</study_first_submitted>
  <study_first_submitted_qc>April 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2007</study_first_posted>
  <last_update_submitted>April 24, 2008</last_update_submitted>
  <last_update_submitted_qc>April 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Vickie Edwards</name_title>
    <organization>Applied Physiology Pty Ltd</organization>
  </responsible_party>
  <keyword>mean systemic pressure</keyword>
  <keyword>fluid therapy</keyword>
  <keyword>closed loop control</keyword>
  <keyword>circulation modelling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

